EORTC presentations at CTOS
7 Nov 2016
EORTC will present four abstracts at the Connective Tissue Oncology Society (CTOS) 21st Annual Meeting, which will take place from 9 to 12 Novembre 2016 in Lisbon, Portugal.
Oral abstract session
Second Safety Analysis of A Phase III Randomized Study of Pre-Operative Radiotherapy (RT) Plus Surgery Versus Surgery Alone for Patients With Retro Peritoneal Sarcoma (RPS) – EORTC 62092-22092- STRASS
Oral Session STS: Retroperitoneal STS; Thu 10.11.2016 – 5:10 PM to 5:55 PM
Authors: Sylvie Bonvalot, Rick L. M. Haas, Saskia Litière, Cecile Le Pechoux, Dirk C Strauss, Carol Jane Swallow, Piotr Rutkowski, Chandrajit P. Raut, Michela Lia, Sandrine Marréaud, Alessandro Gronchi
Poster sessions
Prognosis of Patients Receiving First Line Chemotherapy for Advanced Soft Tissue Sarcomas with Locally Advanced Vs Distant Metastasis Vs Both: An EORTC-STBSG Database Analysis
Poster Session 2: STS 095; Friday 11.11.2016 – 6:15 PM to 7:00 PM
Authors: A.J. Verschoor, S. Litière, S. Marréaud, I. Judson, M. Toulmonde, E. Wardelmann, W. van der Graaf, A. Le Cesne, A. Gronchi, H. Gelderblom
Prospective Validation Of A Molecular Signature Predictive Of Response To Trabectedin In Soft-Tissue Sarcomas Within EORTC 62091 Trial
Poster Session 2: STS 096; Friday 11.11.2016 – 6:15 PM to 7:00 PM
Authors: Italiano A, Touati N, Litière S, Butrynski JE, Penel N, Blay JY, Isambert N, Milhem M, Kerst JM, Reyners AKL, Marréaud S, Collin F, Van der Graaf WT, Gelderblom AJ, Gronchi A
Impact on outcome of concomitant administration of gastric acid suppression (GAS) therapy and pazopanib in soft tissue sarcoma (STS) patients treated within EORTC 62043/62072 trials.
Poster Session 2: STS 113; Friday 11.11.2016 — 6:15 PM to 7:00 PM
Authors: Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S, Leahy M, Young R, Mathijssen R, Van Erp NP, Gelderblom AJ, Van der Graaf WT, Gronchi A
Pazopanib In Advanced Vascular Sarcomas: An EORTC Soft Tissue And Bone Sarcoma Group Retrospective Analysis
Poster Session 2: STS 123; Friday 11.11.2016 — 6:15 PM to 7:00 PM
Authors: Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Boccone P, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litière S, Marréaud S, Gronchi A, Kasper B
Related News
Meet the new EORTC Board
9 Jul 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
17 Jun 2024
Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
20 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Apr 2024
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024